
Krsnaa Diagnostics Q1 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
No
Order
Yes
Capex
Yes
2 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 2- The company targets a revenue growth of 30-35% year-on-year for the next two years excluding Rajasthan.
- With Rajasthan tender included, the growth rate will be significantly higher.
- Rajasthan is expected to contribute close to INR 300 crores in revenue in FY25.
- Total revenue including Rajasthan for FY25 is projected to approach INR 1100 crores.
- New project deployments in Assam, Odisha, BMC, and Maharashtra are expected to drive growth.
- Ramp-up in existing projects like Punjab and Himachal Pradesh continues to contribute to increasing revenues.
- Expansion in pathology service contribution is expected to improve overall revenue mix over time.
- There is headroom for increased tele-reporting and utilization of installed equipment capacity, indicating further volume growth potential.
See what Krsnaa Diagnostics management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- Currently, Krsnaa Diagnostics does not expect to raise any new debt for planned CAPEX.
- CAPEX is primarily funded through internal accruals and some vendor financing (deferred payment or leasing of equipment).
- Debt raising is considered only if a new tender warrants it.
- There is no mention of imminent equity fundraising.
- Cash on the balance sheet (~220 crores) will be utilized for working capital.
- Future fundraising decisions will depend on new tender opportunities and project requirements.
See what Krsnaa Diagnostics management said on order book — free account, 30 seconds.
Capex plans
Yes- Total CAPEX guidance for FY24 and FY25 is approximately ₹120-130 crore each year, totaling around ₹240-260 crore over two years.
- Rajasthan tender alone has a projected CAPEX of close to ₹200 crore, with major spending planned in H2 FY24 and Q1 FY25.
- CAPEX for other projects like Odisha, Assam, and Punjab is relatively lower, estimated around ₹40-60 crore.
- The company primarily plans to fund CAPEX through internal accruals and vendor financing (deferred payment or lease of equipment).
- No major debt raises planned for CAPEX unless new tenders require it.
- Strategic investments focus on deploying equipment and setting up infrastructure in new government PPP projects, including Rajasthan, Assam, Odisha, Maharashtra, and BMC contracts.
- CAPEX is mainly for setting up collection centers, pathology labs, and radiology equipment as per government tender requirements.
Track Krsnaa Diagnostics — get its next earnings analysis in your feed
How does Krsnaa Diagnostics rank vs peers in Healthcare Services?
Pro featureHow does Krsnaa Diagnostics rank in Healthcare Services?
Compare Krsnaa Diagnostics against every Healthcare Services company (Q1 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Krsnaa Diagnostics's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.